US FDA approves AstraZeneca's self-administered nasal spray flu vaccine
The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for ...
FDA approves first self-administered flu vaccine spray
The Food and Drug Administration announced Friday it had broadened the approval of the FluMist nasal spray to become the ...
US FDA approves AstraZeneca's flu vaccine for self-administration
FluMist is the first vaccine to prevent influenza that does not need to be administered by a healthcare provider, the ...
AstraZeneca PLC ADR outperforms competitors despite losses on the day
AstraZeneca PLC ADR closed $9.15 short of its 52-week high ($87.68), which the company reached on August 30th.
Sanofi, AstraZeneca win US approval for RSV therapy manufacturing line
Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...
AstraZeneca PLC ADR rises Monday, outperforms market
The AstraZeneca PLC ADR AZN inched 0.98% higher to $79.04 Monday, on what proved to be an all-around mixed trading session ...
Healthy 27-year-old died after NHS wrongly gave him AstraZeneca Covid jab
A healthy 27-year-old died from a reaction to the AstraZeneca Covid vaccine after NHS mistakes meant he wrongly got the jab, ...
FDA approves first self-administered flu vaccine
The vaccine FluMist, manufactured by MedImmune, which was acquired by AstraZeneca in 2007, was first approved by the FDA in 2003 for individuals between five and 49 years of age. Its approval has ...
WAPT1d
FDA approves first flu vaccine that can be self-administered at home
FluMist is a nasal spray manufactured by AstraZeneca that has been used to protect against influenza in the United States ...
devdiscourse5h
Regulatory Milestones and Health Advances: Key Developments in the Pharmaceutical Sector
Recent health news highlights key regulatory approvals and legal actions. The EU backs Novo Nordisk's Wegovy for an ...
Astrazeneca (AZN) Suffers a Larger Drop Than the General Market: Key Insights
The most recent trading session ended with Astrazeneca (AZN) standing at $78.38, reflecting a -0.66% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's ...
AstraZeneca’s Fasenra meets primary endpoint in Phase III rare vasculitis trial
The Phase III trial compared the efficacy of Fasenra with the standard treatment of GSK’s Nucala in patients with ...